Evidence map›Paper›PMID 27261670›Full record

Trial reportJournal of addiction medicine

Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence: A Case Series.

Jose M Trigo, Alexandra Soliman, Gregory Staios, Lena Quilty, Benedikt Fischer, Tony P George, Jürgen Rehm, Peter Selby, Allan J Barnes, Marilyn A Huestis and 1 more

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
5.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pharmacotherapies for cannabis use disorder.The Cochrane database of systematic reviews · 2025
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pharmacotherapies for cannabis dependence.The Cochrane database of systematic reviews · 2019
    Pooled it
  5. Trial
  6. Review
  7. THC and CBD: Villain versus Hero? Insights into Adolescent Exposure.International journal of molecular sciences · 2023
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Preclinical Studies of Cannabinoid Reward, Treatments for Cannabis Use Disorder, and Addiction-Related Effects of Cannabinoid Exposure.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Jose M TrigoTranslational Addiction Research Laboratory, Campbell Family Mental Health, Research Institute (JMT, AS, GS, BLF); Clinical Research (LQ); Social and Epidemiological Research Department (BF, JR); Schizophrenia Division and Complex Mental Illness Program, Centre for Addiction and Mental Health (CAMH), Toronto, Canada (TPG); Addiction Policy, Dalla Lana School of Public Health (JR); Institute of Medical Science, University of Toronto, Faculty of Medicine (BF, JR); Department of Psychiatry, University of Toronto, Toronto, Canada (BF, TPG, JR, PS); Institute of Clinical Psychology and Psychotherapy & Center of Clinical Epidemiology and Longitudinal Studies (CELOS), Technische Universität Dresden, Dresden, Germany (JR); Addictions Division, CAMH (PS, BLF); Department of Family and Community Medicine, University of Toronto, Toronto (PS); Centre for Applied Research in Mental Health & Addiction, Faculty of Health Sciences, Simon Fraser University, Vancouver, Canada (BF); and Chemistry and Drug Metabolism, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, MD (AJB, MAH).
Alexandra Soliman
Gregory Staios
Lena Quilty
Benedikt Fischer
Tony P George
Jürgen Rehm
Peter Selby
Allan J Barnes
Marilyn A Huestis
Bernard Le Foll
British Lung Foundation · GBCentre for Addiction and Mental Health · CA

Funding

Sativex associated with behavioural-relapse prevention strategy as treatment for cannabis dependenceR21DA031906 · NIDA · CENTRE FOR ADDICTION AND MENTAL HEALTH · PI LE FOLL, BERNARD · 2011 to 2016
$334k
NIDA NIH HHS R21 DA031906
6 · The paper itself

Abstract

objectivesCannabis is the most commonly used illicit drug; a substantial minority of users develop dependence. The current lack of pharmacological treatments for cannabis dependence warrants the use of novel approaches and further investigation of promising pharmacotherapy. In this case series, we assessed the use of self-titrated dosages of Sativex (1:1, Δ-tetrahydrocannabinol [THC]/cannabidiol [CBD] combination) and motivational enhancement therapy and cognitive behavioral therapy (MET/CBT) for the treatment of cannabis dependence among 5 treatment-seeking community-recruited cannabis-dependent subjects.

methodsParticipants underwent a 3-month open-label self-titration phase with Sativex (up to 113.4 of THC/105 mg of CBD) and weekly MET/CBT, with a 3-month follow-up.

resultsSativex was well-tolerated by all participants (average dosage 77.5 THC/71.7 mg CBD). The combination of Sativex and MET/CBT reduced the amount of cannabis use and progressively reduced craving and withdrawal scores. THC/CBD metabolite concentration indicated reduced cannabis use and compliance with medication.

conclusionsIn summary, this pilot study found that with Sativex in combination with MET/CBT reduced cannabis use while preventing increases in craving and withdrawal in the 4 participants completing the study. Further systematic exploration of Sativex as a pharmacological treatment option for cannabis dependence should be performed.

Indexed as

Outcome Assessment, Health CareAdultCannabidiolCognitive Behavioral TherapyCombined Modality TherapyDronabinolDrug CombinationsFemaleFollow-Up StudiesHumansMaleMarijuana AbuseMiddle AgedMotivational InterviewingPilot ProjectsPlant ExtractsCannabidiolDronabinolDrug CombinationsnabiximolsPlant Extracts

Identifiers

PMID27261670
PMCPMC5586546
OpenAlexW2416318581

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.